|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, it is urgent to develop a new category of anti-nephropathy medicine directly targeting renin.
|
30308499 |
2018 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Inhibition of the renin-angiotensin system reduces the risk of kidney disease progression and treatments that lower blood pressure (BP) or low-density lipoprotein cholesterol reduce cardiovascular (CV) risk in this population.
|
30524708 |
2018 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this study, we describe a mouse model combining type 1 diabetes with activation of the renin-angiotensin system (RAS), which develops robust kidney disease with features resembling human DN: heavy albuminuria, hypertension, and glomerulosclerosis.
|
30065034 |
2018 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Inhibition of the renin-angiotensin system in early postnatal life is a potential therapeutic approach to prevent long-term cardiovascular and kidney diseases in individuals born small.
|
29870806 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Genetic variability in the genes of various components of the renin-angiotensin system may play a role in the pathogenesis of the kidney disorders.
|
29891744 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Among patients with proteinuric chronic kidney disease (CKD), current guideline recommendations mandate the use of agents blocking the renin angiotensin aldosterone system (RAAS) as first-line antihypertensive therapy based on randomized trials demonstrating that RAAS inhibitors are superior to other antihypertensive drug classes in slowing nephropathy progression to end-stage renal disease.
|
29276100 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin-aldosterone system (RAAS) plays important roles in regulating renal hemodynamics and functions, as well as in the pathophysiology of hypertension and renal disease.
|
29600408 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Imarikiren hydrochloride (TAK-272/SCO-272) is a novel direct renin inhibitor with potential indications for cardiovascular and renal diseases.
|
29845723 |
2018 |
|
Kidney Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thus targeted γ-secretase-based prodrugs developed as substrates for γ-GT/γ-GCT have the potential to selectively control Notch activation in kidney diseases with subsequent regulation of the inflammatory stress response and the renin-angiotensin pathways.
|
28971991 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial hypertension as well as in more complex mechanisms of cardiovascular and renal diseases.
|
28598381 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The renin-angiotensin system (RAS) plays an important role in the initiation and progression of cardiovascular and renal diseases.
|
28694144 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Hypertension is an inflammatory condition controlled by the renin angiotensin system and is linked to kidney disease, diabetes mellitus, and recently to dysfunction of the gut.
|
27903643 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Klotho suppresses the renin-angiotensin system in adriamycin nephropathy.
|
27798196 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The importance of the RAS in the development and pathogenesis of cardiovascular, hypertensive and kidney diseases has now been firmly established in clinical trials and practice using renin inhibitors, angiotensin-converting enzyme (ACE) inhibitors, type 1 (AT<sub>1</sub>) angiotensin II (ANG II) receptor blockers (ARBs), or aldosterone receptor antagonists as major therapeutic drugs.
|
28619367 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin-aldosterone system inhibitors (RAASIs), including angiotensin-converting enzyme inhibitors, angiotensin AT1 receptor blockers and mineralocorticoid receptor antagonists (MRAs), are the cornerstone for the treatment of cardiovascular and renal diseases.
|
28541811 |
2017 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Despite optimal therapy of diabetic nephropathy with agents blocking the renin-angiotensin-aldosterone system, the residual risk of nephropathy progression to end-stage renal disease (ESRD) remains high.
|
28520568 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Abbreviations BMI = body mass index BP = blood pressure CH = hypertensive crisis ContrHT = controlled hypertensive DBP = diastolic blood pressure GFR = glomerular filtration rate HbA1c = glycated hemoglobin HDLc = high-density lipoprotein cholesterol HE = hypertensive emergency HPLC = high-performance liquid chromatography HR = heart rate HU = hypertensive urgency JNC 7 = VII Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure LDLc = low-density lipoprotein cholesterol MDRD = Modification of Diet in Renal Disease NT = normotensive RASB = renin-angiotensin system blockers SBP = systolic blood pressure TC = total cholesterol TG = triglycerides.
|
28569557 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Despite multiple clinical trials of various interventions including dual blockade of the renin-angiotensin system over the past 15 years, no new therapies have emerged to slow kidney disease progression in diabetes.
|
28743130 |
2017 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We report a novel dominant REN mutation discovered in an individual after forty years of renal disease.
|
28701203 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
What is Known: • Renal renin-angiotensin system (RAS) has several pathophysiologic functions not only in blood pressure regulation but also in pediatric renal disease.
|
27995362 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme 2 (ACE2) is a recently described member of the renin-angiotensin system that hydrolyzes angiotensin (Ang) II to Ang-(1-7), and may thereby protect against cardiovascular and renal diseases.
|
28116710 |
2017 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors and/or angiotensin II type 1 receptor blockers is the most effective treatment to achieve these purposes in non-diabetic and diabetic proteinuric renal diseases.
|
28482281 |
2017 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The 2012 Kidney Disease Improving Global Outcome (KDIGO) guidelines suggest giving corticosteroids to patients with rather preserved renal function (GFR>50 ml/min per 1.73 m<sup>2</sup>) and persistent proteinuria >1 g/d, despite 3-6 months of optimized supportive care with renin-angiotensin system blockers.
|
27671778 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Pivotal RCTs in the nephrology area efficiently demonstrated the renoprotective effects of treatment with renin-angiotensin system inhibitors in patients with diabetic and non-diabetic proteinuric nephropathies.
|
27643796 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Role of the intrarenal renin-angiotensin system in the progression of renal disease.
|
27380400 |
2017 |